What is Haemonetics's apheresis — R&D?

Haemonetics (HAE) reported apheresis — R&D of $6.38M in Q2 2026.

What does apheresis — R&D mean?

This represents the investment made by the Apheresis segment into the discovery, development, and improvement of new technologies, products, and clinical solutions. It is a leading indicator of the segment's commitment to innovation and long-term competitive advantage. High spending levels suggest a focus on future product pipeline growth and market differentiation.

Haemonetics (HAE) Apheresis — R&D

Screener

Other segment segments

MedSurg

$9.82M—

Similar metrics at other companies

INSMARIKAYCE external R&D expenses — R&D

$6.23M-43.4%

INSMBrensocatib external R&D expenses — R&D

$13.83M-58.8%

INSMTPIP external R&D expenses — R&D

$38.94M+88.6%

INSMOther external R&D expenses — R&D

$48.84M+71.7%

MUAEBU — R&D

$109M+0.9%

MUCDBU — R&D

$358M+76.4%

Other financials

Income statement

See full

Revenue$339.4M+5.6%

Gross profit$202.8M+5.5%

Operating income$57.5M+6.7%

Net income$33.0M-3.0%

EPS (diluted)$0.72+2.9%

Balance sheet

See full

Cash & equivalents$223.4M-23.7%

Total debt$1.2B-4.1%

Total equity$837.1M-5.1%

Total assets$2.4B-3.9%

Cash flow

See full

Operating cash flow$52.3M+201%

CapEx$7.9M+111%

Free cash flow$44.4M+226%

Valuation

See full

Market cap$3.87B+6.3%

Enterprise value$4.82B+5.4%

P/E25.7×-10.5×

P/S2.9×+0.2×

Profitability

See full

Gross margin59%+2.1pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin21.5%+7.5pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.4×0.0×

Current ratio3.1×+1.4×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Haemonetics’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 6:09 AM EDT
Fiscal quarter: Q1 FY2027
Calendar quarter: Q2 2026
Accession: 0000313143-26-000120

Line item	Three Months Ended / June 27, 2026	Three Months Ended / June 28, 2025
Apheresis
Cost of goods sold	$84,131	$75,865
Selling, general and administrative	44,264	39,880
Research and development	6,378	6,816
Apheresis operating income	$56,545	$59,175
MedSurg
Cost of goods sold	$50,368	$50,216
Selling, general and administrative	65,160	62,323

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Haemonetics's apheresis — R&D?: Haemonetics (HAE) reported apheresis — R&D of $6.38M in Q2 2026.
What does apheresis — R&D mean?: This represents the investment made by the Apheresis segment into the discovery, development, and improvement of new technologies, products, and clinical solutions. It is a leading indicator of the segment's commitment to innovation and long-term competitive advantage. High spending levels suggest a focus on future product pipeline growth and market differentiation.